广告
加载中

元禾璞华陈瑜:我们为何押注脑机接口

吴琼 2026-06-18 08:56
吴琼 2026/06/18 08:56

邦小白快读

EN
全文速览

这篇文章整理了2026投资界SuperLink大会上脑机接口主题圆桌的核心干货,汇总了行业当前发展阶段与未来方向,核心信息如下:

1. 当前脑机接口正处于爆发元年,行业热度极高,国内侵入式脑机接口企业从去年的十几家增长到今年的两百多家,融资活跃,多技术路线并行,但整体仍处于早期,技术尚未收敛。

2. 中美脑机接口发展路径差异明显,美国Neuralink侧重长远的人机交互研发,国内企业普遍偏向务实的康复医疗路线,针对神经损伤失能人群的康复是千亿级市场。国内拥有临床资源、供应链的结构性优势,但技术积累只有不到十年,和美国四五十年的积累仍有差距。

3. 当前行业面临监管门槛高、技术瓶颈等问题,未来行业将出现分水岭,企业会向全链条终端产品、核心细分环节两个方向分化发展。

对于布局脑机接口赛道的品牌商,本文提供了行业趋势、研发方向、竞争策略等多方面干货参考,具体如下:

1. 消费与市场趋势:脑机接口已经进入爆发元年,本质是赛博格人机交互的终极形态,未来会逐步渗透医疗、消费电子、具身智能等多个领域,当前国内神经损伤失能人群康复已经形成千亿级可见市场,赛道整体处于指数上升阶段,增长空间广阔。

2. 产品研发方向:现阶段国内品牌走务实康复路线更符合国情,更容易落地获得收益,同时需要提前布局脑机接口与AI、具身智能的结合,抢占未来技术制高点。

3. 竞争策略参考:当前赛道仍处于早期,技术尚未定型,品牌可选择两条路线建立优势,一是尽快推进产品定型、临床、拿证落地,率先落地就能获得两到三年的市场保护期;二是切入芯片等核心细分环节,打造细分领域竞争力。

对于想要进入脑机接口赛道的创业者和卖家,本文整理了机会提示、风险提示与行动方向,干货内容如下:

1. 市场机会:当前脑机接口处于爆发早期,国内康复赛道已经显现千亿级市场空间,随着AI技术商业化落地,未来还会在消费电子、具身智能等领域打开更大增长空间,国内行业整体处于指数增长阶段,创业机会充足。

2. 监管风险提示:国内所有医疗用途的脑机接口产品统一按三类医疗器械证监管,取证和验证周期长,资金投入大,卖家进入前需要做好长期投入的准备,警惕资金链断裂风险。

3. 发展方向参考:未来行业会明显分化,卖家可根据自身资源选择方向,资金技术充足的团队可做全链条终端产品,抢占先发优势;侧重技术研发的团队可聚焦芯片等关键细分环节,做产业链的核心供应商。

对于想切入脑机接口赛道的生产制造类工厂,本文梳理了市场需求、商业机会与转型方向,干货内容如下:

1. 产品生产需求:脑机接口行业处于爆发早期,赛道玩家快速增长,目前已经有上百家企业布局不同技术路线,包括侵入式、视觉重建、超声脑机接口等方向,对核心原材料、基础器件、生产制造的需求持续增长,国内本身就有供应链和制造端的结构性优势,相比美国更有竞争力。

2. 商业机会:未来脑机接口行业会分化出大量细分分工,大部分创业企业会侧重技术研发或终端产品运营,会将生产制造环节对外释放,工厂可依托现有制造能力切入脑机接口供应链,开辟新的增长曲线。

3. 转型启示:脑机接口是AI时代的前沿硬核赛道,工厂可依托自身在半导体制造领域的积累,主动对接投资机构和创业企业,抓住产业升级机会,推进自身的技术升级与业务转型。

对于服务硬科技赛道的服务商来说,本文整理了脑机接口行业的发展趋势、客户痛点与服务机会,干货内容如下:

1. 行业发展趋势:脑机接口已经进入爆发元年,赛道热度快速提升,国内侵入式脑机接口企业一年间从十几家增长到两百多家,头部投资机构纷纷布局,行业整体处于指数增长阶段,大量新兴创业企业对第三方专业服务的需求会持续上涨,市场空间广阔。

2. 核心客户痛点:当前行业存在多个明确痛点,监管层面所有医疗类产品都需要三类证,取证周期长,企业缺乏合规、临床对接相关经验;技术层面需要解决性能提升、降低侵入式手术创伤、对接AI与具身智能技术等需求,大部分早期企业还存在融资对接需求。

3. 服务机会:服务商可针对性开发合规咨询、临床试验资源对接、投融资对接、技术研发合作等服务,满足不同阶段企业的需求,挖掘新的业务增长点。

对于布局硬科技赛道的平台商来说,本文梳理了市场需求、运营方向与风险规避要点,干货内容如下:

1. 市场需求:AI时代,前沿硬核科技成为产业和资本布局的热点,原本聚焦半导体的投资机构已经开始向脑机接口、可控核聚变、量子计算等赛道延伸,大量创业企业有对接资本、产业、临床资源的需求,平台可针对性开拓新的业务板块。

2. 运营与招商方向:平台可围绕脑机接口等前沿赛道举办行业交流活动,对接产资研资源,满足创业企业的合作需求;招商可优先引入有明确技术路线、完成早期布局的项目,优先支持走务实康复路线、明确发展方向的企业。

3. 风向规避:脑机接口赛道仍处于早期阶段,技术尚未收敛,落地周期长,监管门槛高,平台需要提示早期投资研发的风险,引导行业理性发展,避免过度炒作带来的行业乱象。

对于研究脑机接口产业和硬科技投资的研究者来说,本文披露了大量产业新动向、新问题与行业判断,干货内容如下:

1. 产业新动向:脑机接口已经进入爆发元年,中国走出了一条和美国完全不同的务实发展路径,美国侧重长远人机交互研发,中国侧重康复医疗落地;投资领域也出现新动向,原本聚焦半导体的头部投资机构开始依托能力底座,将投资能力迁移到脑机接口等多个前沿硬核赛道,元禾璞华的底座赋能模式是VC行业的新进化方向。

2. 行业新问题:当前国内脑机接口技术积累不足,统一按三类证监管推高了行业落地门槛,同时还存在性能不足、侵入式创伤大等核心技术瓶颈,这些问题都值得深入研究。

3. AI产业发展新判断:当前AI处于基建期后期和商业化落地元年的交汇点,2026-2027年是B端商业化兑现的关键节点,自主创新是长期主线,这些判断对研究AI产业发展有重要参考价值。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article compiles key takeaways from the brain-computer interface (BCI) roundtable discussion at the 2026 SuperLink Investment Conference, outlining the industry's current development stage and future outlook:

1. BCI has now entered its first year of explosion, with rapidly growing industry attention. In China, the number of invasive BCI companies has jumped from around a dozen last year to over 200 this year. The sector sees active financing and multiple parallel technology tracks, but it remains in an early stage overall with no technological convergence yet.

2. China and the U.S. have adopted distinctly different development paths. U.S.-based Neuralink focuses on long-term human-computer interaction R&D, while most Chinese companies prioritize practical rehabilitation medicine applications. The rehabilitation market for people with nerve damage and disabilities is already a 100-billion-yuan market in China. China holds structural advantages in clinical resources and supply chains, but its local technology accumulation of less than 10 years still lags behind the U.S.'s 40 to 50 years of development.

3. The industry currently faces challenges including high regulatory barriers and technical bottlenecks. A clear industry watershed will emerge in the coming years, with companies splitting into two major development tracks: end-to-end finished product development, or specialization in core niche segments.

This article provides valuable insights on industry trends, R&D directions and competitive strategies for brands eyeing entry into the BCI track:

1. Consumer and market trends: BCI has entered its breakout year; it is essentially the ultimate form of cyborg human-computer interaction, and will gradually penetrate sectors including healthcare, consumer electronics and embodied intelligence. Today, the rehabilitation market for people with nerve damage and disabilities in China is already a visible 100-billion-yuan market. The overall track is in an exponential growth phase with huge room for expansion.

2. Product R&D direction: For Chinese brands, focusing on practical rehabilitation applications aligns better with domestic market conditions and enables faster commercialization and revenue generation. At the same time, brands should proactively layout for the integration of BCI with AI and embodied intelligence to secure a leading position in future technology development.

3. Competitive strategy references: The track remains in an early stage with an undefined technical standard, so brands can build competitive advantages via two paths: either speed up product finalization, clinical trials and regulatory approval to launch early, which will secure a 2-3 year market protection window; or enter core niche segments such as BCI chips to build specialized competitive strength.

This article summarizes opportunity alerts, risk warnings and action directions for entrepreneurs and sellers looking to enter the BCI track:

1. Market opportunities: BCI is in the early stage of an explosion, with a 100-billion-yuan market already visible in China's rehabilitation segment. As AI commercialization accelerates, BCI will unlock even larger growth potential in consumer electronics, embodied intelligence and other sectors. China's BCI industry is in an exponential growth phase, with abundant entrepreneurial opportunities.

2. Regulatory risk warning: All medical-use BCI products in China are regulated as Class III medical devices, which requires long approval and validation cycles and heavy capital investment. Sellers must prepare for long-term commitment before entering the market and guard against the risk of capital chain rupture.

3. Development direction references: The industry will see clear segmentation in the future, and sellers can choose their direction based on existing resources. Teams with sufficient capital and technical strength can develop end-to-end end products to capture first-mover advantage; teams focused on R&D can specialize in key niche segments such as chips to become core suppliers in the industrial chain.

This article outlines market demand, business opportunities and transformation directions for manufacturing factories looking to enter the BCI track:

1. Production demand: The BCI industry is in the early stage of an explosion, with the number of industry players growing rapidly. More than 100 Chinese companies are already active across different technology tracks, including invasive BCI, visual reconstruction, and ultrasonic BCI. This drives steadily growing demand for core raw materials, basic components and manufacturing services. China's inherent structural advantages in supply chains and manufacturing make it more competitive than the U.S. in this area.

2. Business opportunities: The BCI industry will split into a large number of specialized niches going forward. Most startups will focus on in-house R&D or end product operation, and outsource manufacturing. Factories can leverage their existing manufacturing capabilities to enter the BCI supply chain and unlock a new growth curve.

3. Transformation insights: BCI is a cutting-edge hard tech track in the AI era. Factories can build on their existing experience in semiconductor manufacturing, actively connect with investment institutions and startups, and seize industrial upgrading opportunities to drive their own technical transformation and business expansion.

This article summarizes BCI industry trends, customer pain points and service opportunities for hard tech-focused service providers:

1. Industry development trends: BCI has entered its breakout year, with rapidly growing industry heat. In China, the number of invasive BCI companies has surged from around a dozen to more than 200 in just one year, with leading investment institutions rushing to layout the sector. The overall industry is in an exponential growth phase, so demand for third-party professional services from a growing number of startups will continue to rise, creating enormous market space.

2. Core customer pain points: The industry has several clear pain points. On the regulatory side, all medical BCI products require Class III medical device approval, which has a long cycle, and most startups lack experience in compliance and clinical trial connection. On the technical side, companies need solutions to improve performance, reduce invasive surgical trauma, and integrate AI and embodied intelligence technologies. Most early-stage startups also need support for financing connection.

3. Service opportunities: Service providers can develop targeted offerings including compliance consulting, clinical trial resource connection, investment and financing matching, and R&D cooperation to meet the needs of companies at different stages and unlock new business growth points.

This article sorts out market demand, operation directions and risk mitigation guidelines for platform operators active in the hard tech space:

1. Market demand: In the AI era, cutting-edge hard technology has become a focus for industry and capital布局. Investment institutions originally focused on semiconductors are expanding into BCI, controlled nuclear fusion, quantum computing and other new tracks. A large number of BCI startups need access to capital, industrial and clinical resources, so platforms can develop targeted new business segments to meet this demand.

2. Operation and investment promotion directions: Platforms can organize industry events focused on cutting-edge tracks such as BCI to connect industry, capital and research resources to meet startups' cooperation needs. For investment promotion, platforms should prioritize projects with clear technology roadmaps and early布局, and give priority to supporting companies that adopt the practical rehabilitation route and have a clear development strategy.

3. Risk mitigation: The BCI track remains in an early stage with no technological convergence, long commercialization cycles and high regulatory barriers. Platforms need to clearly disclose the risks of early-stage investment and R&D, guide rational industry development, and avoid market chaos caused by overhyping.

This article discloses a large number of new industry trends, emerging issues and industry judgments for researchers focused on BCI industry and hard tech investment:

1. New industry trends: BCI has entered its breakout year, and China has developed a distinctly pragmatic development path different from that of the U.S. While the U.S. focuses on long-term human-computer interaction R&D, China prioritizes commercialization in rehabilitation medicine. In the investment space, leading institutions originally focused on semiconductors are leveraging their existing capabilities to expand investment into BCI and other cutting-edge hard tech tracks. Yuanhe Puhua's "base empowerment" model represents a new evolution direction for the VC industry.

2. Emerging industry issues: China currently lacks sufficient long-term technology accumulation in BCI. The uniform Class III regulatory classification for all medical BCI products raises the barrier to market entry. The industry also faces core technical bottlenecks including insufficient product performance and high trauma from invasive procedures. All these issues are worthy of in-depth research.

3. New judgments on AI industry development: AI is currently at the intersection of the late infrastructure stage and the first year of commercialization. 2026-2027 will be a critical period for B-end commercialization delivery, and independent innovation will remain the long-term core theme. These judgments provide important reference value for research on AI industry development.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

脑机接口火爆历历在目。

近日,由清科控股(01945.HK)、投资界主办,吴中金控集团联合主办的“2026投资界SuperLink大会”于苏州举行。现场,元禾璞华合伙人陈瑜与东微半导创始人龚轶、脑器时代创始人郭亮、念通智能总经理束小康以《脑机接口,赛博格时代真的来了吗》为主题,进行了一场圆桌对话。

说起来,元禾璞华是国内半导体标杆性投资机构,至今累计管理资金规模超200亿元,投资项目超250个,迄今已培育出韦尔股份、华大九天、华勤技术、江波龙、思瑞浦、纳芯微、澜起科技等50多家上市公司。

而在前不久,元禾璞华落子一笔脑机接口——完成对脑器时代种子轮的领投。这是行业风向变化的一缕缩影:过往聚焦在半导体的投资机构,进入AI时代,开始将触角延伸至更科幻的赛道。

赛博格时代

脑机接口热潮席卷

肉眼可见,脑机接口正迎来爆发元年。

东微半导创始人龚轶对此感受颇深——“去年我的视野里大概有十几家侵入式脑机接口公司,今年听说已经有两百多家,融资火热,各种技术路线都在涌现。”

而元禾璞华的布局,某种程度上反映了脑机接口行业现状——赛道热闹,却尚处于早期,技术尚未收敛。元禾璞华合伙人陈瑜回忆,面对这一全新赛道,她带领团队对各个技术路线全面扫描,逐一拜访二十多家头部公司,并从中挑选了3-4家进行早期布局。目前,元禾璞华已多点布局侵入式脑机接口、视觉重建脑机接口、超声脑机接口等路线。

在龚轶看来,中国企业正走出一条与美国截然不同的务实路径。与美国Neuralink聚焦脑控、视觉恢复以及更长远的人机交互带宽提升不同,中国企业普遍向康复路线收敛,“针对神经系统损伤的失能人群的康复,是千亿级的市场。”

但热闹之下,仍需保持冷静的自我认知。脑器时代创始人郭亮给出一组数据:中国侵入式脑机接口科研不到十年,而美国已有四五十年历史。“客观地说,我们在这方面尚未能与美国并驾齐驱。”

郭亮指出,中国的结构性优势在于——第一,临资源丰富,神经外科医生的手术水平高,且拥有大量病人资源参与临床试验;第二,生产制造、原材料和基础器件等方面的供应链优于美国。他比喻道:“如果美国过去20年的发展是一条上升的直线,我们当下的发展则是一条上升的指数曲线。”

对于脑机接口当下所处阶段,念通智能总经理束小康认为,虽然过去三到五年行业发展很快,但绝大部分企业都在“摸着石头过河”。核心原因在于监管力度——国内无论是侵入式还是非侵入式,医疗用途的脑机接口统一按三类证监管。这意味着,所有产品都必须拿到三类注册证才能上市,对企业而言,这是漫长的取证和验证过程。

分水岭即将到来。未来,脑机接口企业将向两个方向进化——一是做终端产品,掌握整套技术,谁能尽快完成定型、临床、拿证、产品落地,谁就能获得两三年甚至更长的市场保护期。二是在技术链条中做细分环节,比如芯片等关键环节。

关于大家期待的赛博格时代,三位创始人提出一个有趣的观点:赛博格时代已经到来——人类不断与电子设备进行信息交换,这已是赛博格。不过束小康指出,人体处理外界信息效率最高的器官是大脑,“脑机接口将是终极形态”。

那么,脑机接口如何更好地与AI和具身智能对接?郭亮认为,这在技术上仍面临着两大挑战:一是性能的大幅提升,二是易用性。目前,即使是侵入式脑机接口,性能仍然有限;更大的问题在于,侵入式手术对人体带来的创伤很大。这严重阻碍了产品在医疗器械领域的落地,更不用说消费级可穿戴智能硬件。“脑机接口要产生更大产业、经济和社会影响,必须在性能和易用性上实现重大突破。”

龚轶则描述了更具想象力的场景:未来具身智能机器人有望通过人类神经信号完成训练迭代,一步步获得自主行动能力,实现《阿凡达》里人类数字孪生的奇幻未来。而圆桌之外,元禾璞华正用真金白银将这一图景转化为具体的产业布局。

AI时代

一个VC进化样本

产业潮水的更迭,也深刻影响着投资机构的命途。

过往元禾璞华留给外界的深刻印象,是国内集成电路产业链近年来最成功、最活跃的投资团队之一。当下头部半导体项目背后,大多都有元禾璞华的身影。如今,这支团队意外出现在脑机接口赛道。

深究下来,这是面对AI时代的主动进化。黄仁勋把AI生态比作一块“五层蛋糕”:分别包括能源、芯片、基础设施、模型和应用。AI浪潮带来的,则是长达8至10年的全新增量周期,这将催生大量新产品形态,新的创业浪潮。元禾璞华不但出手大模型、具身智能赛道,更是积极投向未来前沿科技赛道,包括脑机接口、可控核聚变、量子计算等。其中不乏月之暗面、阶跃星辰、原力灵机、乐享智能、造物时代、星环聚能等明星项目。

不仅如此,元禾璞华的打法有着清晰的逻辑内核。陈瑜将这一进化路径概括为“底座赋能”——团队出身半导体,对“最硬的科技”有着天然的理解力和判断力。在此基础上,只需将新的行业数据持续输入“大脑”进行训练,便能将投资能力迁移至任何硬核赛道。“我们投资人的进化,其实也是一个个模型产生的过程。”

谈及未来十年,陈瑜判断,当前AI处于基建期后期和商业化落地元年的交汇点。2026-2027年是B端商业化兑现的关键时间点。2028年之后,随着基建逐步完善,AI将全面渗透到工业、政企、医疗、汽车等领域,成为标配生产力工具。

她强调,与半导体“先海外后国产替代”路线不同,AI时代,中国从第一天起就走在自主创新的路上——国模配国芯,将是贯穿整个周期的长期主线。而更伟大的AI公司,或许尚未诞生。

正如移动互联网浪潮中,字节跳动、美团等巨头均诞生于浪潮中后期。中国AI的终局,远比此刻所见更加辽阔。

注:文/吴琼,文章来源:投资界(公众号ID:pedaily2012),本文为作者独立观点,不代表亿邦动力立场。

文章来源:投资界

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0